Centre Hospitalier Alpes Leman

At Centre Hospitalier Alpes Leman, the Medical Oncology team is running a broad portfolio of studies in cancer care, with a strong focus on improving treatment options for lung cancer, breast cancer, colon cancer, ovarian cancer, and lymphoma. These trials are designed to test new therapies, refine treatment strategies, and better match care to patients’ disease features.

• Research in non-small cell lung cancer and small cell lung cancer is evaluating whether newer immunotherapy and targeted approaches can improve survival and disease control.
• Studies in breast cancer are exploring personalized treatment choices, including options for HER2-positive, HER2-negative, and hormone receptor-positive disease.
• Work in colon cancer and rectal cancer is focused on tailoring adjuvant treatment and identifying patients most likely to benefit from additional therapy.
• Trials in ovarian cancer and peripheral T-cell lymphoma are assessing whether treatment intensification or transplantation can improve outcomes in higher-risk disease.

Overall, this oncology program emphasizes therapeutic innovation, precision medicine, and better long-term outcomes for patients with advanced or high-risk cancers.

The site is active in respiratory disease research, especially studies involving non-small cell lung cancer, small cell lung cancer, and other advanced lung malignancies. The main goal is to evaluate whether newer combinations of immunotherapy, chemotherapy, and targeted therapy can improve survival and reduce relapse.

• Trials in lung cancer are testing new treatment strategies for both newly diagnosed and previously treated patients.
• Research includes approaches aimed at improving progression-free survival and overall survival in difficult-to-treat disease.
• Some studies focus on using molecular markers to guide more individualized treatment decisions.
• The work supports better treatment selection for patients with advanced thoracic cancers.

This respiratory research reflects a strong interest in making lung cancer care more effective and more precisely targeted.

Clinical trials in digestive system diseases at this center mainly address colon cancer and rectal cancer. These studies aim to improve postoperative care, refine the use of adjuvant chemotherapy, and identify patients who may benefit from treatment guided by biomarkers such as circulating tumor DNA.

• Studies in colon carcinoma are evaluating how to better reduce recurrence risk after surgery.
• Research in older adults with stage III colon cancer is examining ways to optimize treatment while balancing benefit and tolerability.
• Some trials use blood-based tumor DNA to help guide decisions about further therapy.
• Work in upper rectal cancer is focused on comparing strategies that may improve relapse-free outcomes.

These studies aim to make gastrointestinal cancer treatment more precise and better aligned with individual risk.

Within bacterial infection research, the site is involved in studies of difficult-to-treat staphylococcal prosthetic joint infection. The purpose is to improve infection management and compare antibiotic strategies that may support recovery while preserving implanted joints when possible.

• Research addresses prosthetic joint infection caused by staphylococci.
• Trials are assessing whether alternative oral antibiotic approaches can maintain effectiveness.
• The broader aim is to improve outcomes in orthopedic infection care.
• These studies help refine treatment choices in complex infectious disease settings.

This area highlights practical research focused on better control of serious bacterial infections.

The neurology research portfolio includes studies in multiple sclerosis. These trials are designed to test whether newer therapies can reduce relapses and improve disease control for people living with this chronic central nervous system condition.

• Research in relapsing multiple sclerosis is comparing newer treatment options with established therapy.
• The main focus is on lowering the frequency of confirmed relapses.
• Studies are also looking at longer-term treatment benefit and durability.
• This work supports more effective management of immune-mediated neurological disease.

These trials reflect an effort to improve day-to-day disease control and long-term outcomes in multiple sclerosis.

The site also contributes to research on diagnostic and therapeutic techniques, especially studies using circulating tumor DNA, molecular response, and other tools to guide treatment decisions. This work supports more personalized care across several cancer types and helps identify patients who may benefit from changing therapy earlier.

• Trials are evaluating blood-based biomarkers to detect residual disease and guide next treatment steps.
• Some studies focus on using molecular testing to select patients for targeted or antibody-based treatment.
• Research includes strategies to improve the timing of treatment changes when resistance is expected.
• These approaches aim to make precision oncology more effective in routine care.

This area shows a strong emphasis on tools that can improve diagnosis, monitoring, and treatment selection across oncology.